242 related articles for article (PubMed ID: 14985277)
1. Costs associated with combination antiretroviral therapy in HIV-infected patients.
Yazdanpanah Y
J Antimicrob Chemother; 2004 Apr; 53(4):558-61. PubMed ID: 14985277
[TBL] [Abstract][Full Text] [Related]
2. The economics of effective AIDS treatment in Thailand.
Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
[TBL] [Abstract][Full Text] [Related]
3. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.
Marseille E; Saba J; Muyingo S; Kahn JG
AIDS; 2006 Apr; 20(6):907-14. PubMed ID: 16549976
[TBL] [Abstract][Full Text] [Related]
4. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
5. Modeling the use of triple combination therapy in five countries: nevirapine, Zidovudine, and Didanosine.
Biddle AK; Simpson KN
Value Health; 2000; 3(3):186-201. PubMed ID: 16464183
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
[TBL] [Abstract][Full Text] [Related]
7. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002).
Beck EJ; Mandalia S; Youle M; Brettle R; Fisher M; Gompels M; Kinghorn G; McCarron B; Pozniak A; Tang A; Walsh J; Williams I; Gazzard B
Int J STD AIDS; 2008 May; 19(5):297-304. PubMed ID: 18482958
[TBL] [Abstract][Full Text] [Related]
8. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.
Krentz HB; Auld MC; Gill MJ;
CMAJ; 2003 Jul; 169(2):106-10. PubMed ID: 12874156
[TBL] [Abstract][Full Text] [Related]
9. Combined antiviral treatment in HIV infection. Is it value for money?
Davies D; Carne C; Camilleri-Ferrante C
Public Health; 1999 Nov; 113(6):315-7. PubMed ID: 10637527
[TBL] [Abstract][Full Text] [Related]
10. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
[TBL] [Abstract][Full Text] [Related]
11. Economic impact of delaying or preventing AIDS in persons with HIV.
Pinkerton SD; Holtgrave DR
Am J Manag Care; 1999 Mar; 5(3):289-98. PubMed ID: 10351025
[TBL] [Abstract][Full Text] [Related]
12. Providing antiretroviral therapy for HIV infection.
Steinbrook R
N Engl J Med; 2001 Mar; 344(11):844-6. PubMed ID: 11248164
[No Abstract] [Full Text] [Related]
13. Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART.
Stoll M; Claes C; Schulte E; Graf von der Schulenburg JM; Schmidt RE
Eur J Med Res; 2002 Nov; 7(11):463-71. PubMed ID: 12568973
[TBL] [Abstract][Full Text] [Related]
14. [Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012].
Blasco AJ; Arribas JR; Boix V; Clotet B; Domingo P; González-García J; Knobel H; López JC; Llibre JM; Lozano F; Miró JM; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM;
Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):283-93. PubMed ID: 22525829
[TBL] [Abstract][Full Text] [Related]
15. The affordability of antiretroviral therapy in developing countries: what policymakers need to know.
Forsythe SS
AIDS; 1998; 12 Suppl 2():S11-8. PubMed ID: 9792357
[TBL] [Abstract][Full Text] [Related]
16. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy.
Bozzette SA; Joyce G; McCaffrey DF; Leibowitz AA; Morton SC; Berry SH; Rastegar A; Timberlake D; Shapiro MF; Goldman DP;
N Engl J Med; 2001 Mar; 344(11):817-23. PubMed ID: 11248159
[TBL] [Abstract][Full Text] [Related]
17. Economic impact of HIV.
Veenstra N; Whiteside A
Best Pract Res Clin Obstet Gynaecol; 2005 Apr; 19(2):197-210. PubMed ID: 15778110
[TBL] [Abstract][Full Text] [Related]
18. [Cost of HIV treatment in highly active antiretroviral therapy in Japan].
Kimura H
Nihon Rinsho; 2002 Apr; 60(4):813-6. PubMed ID: 11968794
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand.
Ono S; Kurotaki T; Nakasone T; Honda M; Boon-Long J; Sawanpanyalert P; Kimura K
Jpn J Infect Dis; 2006 Jun; 59(3):168-73. PubMed ID: 16785697
[TBL] [Abstract][Full Text] [Related]
20. Treatment adherence improves outcomes and manages costs.
Valenti WM
AIDS Read; 2001 Feb; 11(2):77-80. PubMed ID: 11279875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
